Skip to main content
Onconic Therapeutics Inc. logo

Onconic Therapeutics Inc. — Investor Relations & Filings

Ticker · 476060 ISIN · KR7476060009 KO Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2025-04-02 Regulatory Filings
Country KR South Korea
Listing KO 476060

About Onconic Therapeutics Inc.

http://onconic.co.kr/

Onconic Therapeutics Inc., established in 2020, is a biopharmaceutical company specializing in the research and development of innovative drugs. A subsidiary of Jeil Pharmaceutical, the company focuses on creating novel treatments for cancer and gastrointestinal disorders, including gastroesophageal reflux disease. Its development strategy prioritizes therapeutics for conditions with high unmet medical needs and significant market potential. Onconic Therapeutics actively advances its pipeline of drug candidates through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험결과) (자큐보정과 자큐보구강붕해정의 약동학과 안전성을 비교,평가한 제 1상 임상시험 결과)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from Onconic Therapeutics regarding the results of a Phase 1 clinical trial for a new drug formulation ('Zakubo' orally disintegrating tablet). It details the clinical trial methodology, objectives, and the successful outcome (bioequivalence). This type of disclosure, which reports significant business/clinical developments to the public and regulatory authorities, falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting categories like 10-K or IR, and is not a mere announcement of a report (RPA).
2025-04-02 Korean
투자판단관련주요경영사항 (자큐보정의 새로운 제형으로 개발한 자큐보구강붕해정의 신규 품목허가 민원 신청 (신규 제형 추가를 위한 대한민국 식품의약품안전처 품목허가 민원 신청))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Onconic Therapeutics submitted to the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the application for a new drug product approval (NDA) for a new formulation (orally disintegrating tablet) of an existing drug, Zakubo. Since this is a formal regulatory disclosure of a significant business event (drug approval application) that does not fit into specific categories like financial reports, dividends, or M&A, it is classified as a Regulatory Filing (RNS).
2025-04-02 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides the official outcomes of the shareholder meeting held on 2025-03-24, including the approval of financial statements, board appointments, and other resolutions. This falls directly under the definition of a Declaration of Voting Results.
2025-03-24 Korean
투자판단관련주요경영사항 (파트너사인 Livzon Pharmaceutical Group Inc.에 Zastaprazan(자큐보정)의 생산기술이전 완료 마일스톤 달성에 따른 기술료 청구 )
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Onconic Therapeutics regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing the achievement of a milestone (manufacturing technology transfer) under a licensing agreement with Livzon Pharmaceutical Group Inc. and the subsequent billing of a milestone payment. This type of disclosure regarding material business events, contracts, and financial milestones is classified as a general regulatory filing (RNS) in the provided schema, as it does not fit into specific categories like M&A, dividends, or director dealings.
2025-03-24 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This is a standard regulatory filing used to disclose insider transactions, such as stock option exercises by company directors. In the provided classification schema, 'Director's Dealing' (DIRS) is the specific category for reports of personal share transactions by company directors and executives.
2025-03-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in Korea. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their personal share transactions or changes in ownership. According to the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-03-17 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.